The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2020

Filed:

Apr. 29, 2016
Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventor:

Alan F. List, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 31/454 (2006.01); A61K 38/19 (2006.01); A61K 38/22 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57426 (2013.01); A61K 31/454 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 38/22 (2013.01); G01N 33/574 (2013.01); G01N 33/57407 (2013.01); G01N 33/57484 (2013.01); G01N 33/6893 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/525 (2013.01); G01N 2800/52 (2013.01);
Abstract

A method is disclosed for diagnosing multiple myeloma or myelodysplastic syndrome (MDS) in a subject and/or predicting the responsiveness of a patient with a multiple myeloma or MDS to lenalidomide treatment, erythropoietin treatment, or a combination thereof. The method involves assaying a biological sample from the subject, such as a blood, serum, or plasma sample, for s100A9 protein levels, TNF? levels, or a combination thereof wherein elevated levels of s100A9 in the biological sample and/or reduced levels of TNF? levels is an indication of MDS in the subject and/or that the patient will be responsive.


Find Patent Forward Citations

Loading…